Sigilon Therapeutics Inc.

Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more

Plus: CMO changes at Centessa, Lifordi, Rapport and Gemma, and updates from Peptone, Labgenius, Mitorx and more

Founders see chance to build start-ups from university IP, with clinical infrastructure already in place from local institutions

CVRs accounted for 9-88% of the total share prices in the deals, but comprised less than a third in most cases

By bridging valuation gaps, CVRs have become an increasingly key tool for getting acquisitions done

Lilly limits its risk but sees enough to keep the Type I diabetes cell therapy alive

Plus: Laekna completes $101M Hong Kong IPO, FDA again rebuffs Alvotech’s Humira biosimilar and updates from Vesalius, Alkermes and Vertex Ventures

Pharma partner pays about $35M, gains control of islet therapy slowed by platform setback; CVRs could drive deal value above $300M

Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and more

Comparing the profiles of up-and-coming therapies for Fabry disease